Adamis Pharmaceuticals (NASDAQ: ADMP) and Impax Laboratories (NASDAQ:IPXL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
16.5% of Adamis Pharmaceuticals shares are held by institutional investors. Comparatively, 90.5% of Impax Laboratories shares are held by institutional investors. 12.2% of Adamis Pharmaceuticals shares are held by insiders. Comparatively, 3.2% of Impax Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Adamis Pharmaceuticals and Impax Laboratories’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adamis Pharmaceuticals||$6.47 million||22.45||-$19.43 million||N/A||N/A|
|Impax Laboratories||$824.43 million||1.81||-$472.03 million||($6.25)||-3.22|
Adamis Pharmaceuticals has higher earnings, but lower revenue than Impax Laboratories.
This table compares Adamis Pharmaceuticals and Impax Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Adamis Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Impax Laboratories has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Adamis Pharmaceuticals and Impax Laboratories, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adamis Pharmaceuticals presently has a consensus target price of $10.33, indicating a potential upside of 137.55%. Impax Laboratories has a consensus target price of $20.29, indicating a potential upside of 0.67%. Given Adamis Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adamis Pharmaceuticals is more favorable than Impax Laboratories.
Impax Laboratories beats Adamis Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
About Impax Laboratories
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.